T cells from tdLNs of therapy responders displayed activated phenotypes due to increased expression of the costimulatory molecule CD27, which has been associated with better survival of HNSCC patients during chemotherapy [45]. The gene discussed is CD27; the disease is head and neck squamous cell carcinoma.